There is also a DNA-PK inhibitor called CC-115, which is able to cross the BBB, whose efficacy in patients with GBM is being tested and CC-115 is being considered in combination with radiotherapy and TMZ for GBM (107). Here, PRKDC is linked to glioblastoma.